title: The therapeutic management of a twin pregnancy complicated by the presence of cervical cancer, following laparoscopic staging and chemotherapy, with an emphasis on cisplatin concentrations in the fetomaternal compartments amnion fluid, umbilical cord, and maternal serum.
abstract: OBJECTIVE
  To evaluate the feasibility, toxicity, and pharmacokinetics in the maternal and fetal compartments during chemotherapy in a pregnant patient with cervical cancer.
  
  
  METHODS
  Case report.
  
  
  METHODS
  University Hospital.
  
  
  METHODS
  A 35-year-old woman was diagnosed with an adenocarcinoma FIGO stage IB1 of the cervix uteri at 14 weeks' gestation with twin pregnancy.
  
  
  METHODS
  A laparoscopic transperitoneal pelvic lymphadenectomy was performed at 15 weeks' gestation There was no evidence of lymph node metastases (0/19). The patient decided to continue her pregnancy. Three cycles of neoadjuvant chemotherapy consisting of cisplatin during the second and third trimester were given and well tolerated. Amniocentesis was performed at the time of the second cisplatin cycle. MAIN OUTCOME MEASURE(S) AND RESULT(S): The concentration in the amniotic fluid samples reached 10% of the maternal blood levels at this time. At 32 weeks' gestation, a Caesarean section followed by radical hysterectomy was performed. The twins developed normally and displayed no chemotherapically related side effects. At the time of delivery, the corresponding concentration in the amniotic fluid was approximately one-third of the umbilical cord levels.
  
  
  CONCLUSIONS
  To our knowledge, this is the first report quantifying the amount of transplacental transport of cisplatin during pregnancy in vivo. One-tenth of the maternal serum concentration was detected in the amniotic fluid; the concentration of cisplatin in the umbilical cord was three times higher than in the amniotic fluid.
authors.affiliation: Charité University Hospital, Department of Radiooncology, Berlin, Germany.
authors.forename: Simone
authors.initials: S
authors.lastname: Marnitz
authors.forename: Alexander
authors.initials: A
authors.lastname: Schmittel
authors.forename: Juliane
authors.initials: J
authors.lastname: Bolbrinker
authors.forename: Frank-Peter
authors.initials: FP
authors.lastname: Schmidt
authors.forename: Guus
authors.initials: G
authors.lastname: Fons
authors.forename: Karim
authors.initials: K
authors.lastname: Kalache
authors.forename: Achim
authors.initials: A
authors.lastname: Schneider
authors.forename: Christhardt
authors.initials: C
authors.lastname: Köhler
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D000328:Adult; D000653:Amniotic Fluid / Q000737:chemistry / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002945:Cisplatin / Q000032:analysis / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005240:Feasibility Studies; D005260:Female; D005312:Fetal Blood / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D010535:Laparoscopy; D008431:Maternal-Fetal Exchange / Q000187:drug effects; D009035:Mothers; D009367:Neoplasm Staging / Q000379:methods; D009994:Osmolar Concentration; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy / Q000473:pathology; D011272:Pregnancy, Multiple / Q000187:drug effects; D014427:Twins; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin